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AGMATINE AND AGMATINE ANALOGS IN 
THE TREATMENT OF EPILEPSY, SEIZURE, 
AND ELECTROCONVULSIVE DISORDERS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority from US. Provisional 
Patent Application Ser. No. 60/211,532, ?led Jun. 15, 2000 
entitled “AGMATINE AND AGMATINE ANALOGS IN 
THE TREATMENT OF EPILEPSY, SEIZURE, AND 
ELECTROCONVULSIVE DISORDERS” the entire disclo 
sure of Which is incorporated herein by reference. 
FIELD OF THE INVENTION 
The present invention relates to the use of agmatine and 
analogs thereof in the prevention and treatment of epilep sies, 
seizures, and other electroconvulsive disorders. 
BACKGROUND OF THE INVENTION 
Epilepsy is a general term describing brain disorders that 
are characterized by the occurrence of seizures. Epilepsy 
affects millions of people WorldWide, and over 2.5 million 
individuals in the United States. For the purposes of clinical 
assessment, it is useful to classify patients according to the 
type of seizure the patient experiences. 
As described in The Pharmacological Basis of T herapeu 
tics, seizures can occur periodically or unpredictably. (Good 
man, L. S., et al., Goodman & Gilman's Thepharmacological 
basis of therapeutics. 9th ed. 1996, NeW York: McGraW-Hill 
Health Professions Division. xxi, 1905, Chapter 20). Over 30 
types of epileptic seizures have been described, and they can 
be generally classi?ed into tWo groupsipartial seizures (be 
ginning focally in a cortical site) or generalized seizures 
(involving both brain hemispheres from the outset). Partial 
seizures include simple partial, complex partial and partial 
With secondarily generalized tonic-clonic seizures. General 
ized seizures include absence, myoclonic, atonic, tonic, 
clonic, and tonic-clonic (grand mal) seizures. 
Hundreds of epileptic syndromes have been de?ned as 
disorders characterized by speci?c symptoms that include 
epileptic seizures. These epileptic syndromes include, but are 
not limited to, absence epilepsy, psychomotor epilepsy, tem 
poral lobe epilepsy, frontal lobe epilepsy, occipital lobe epi 
lepsy, parietal lobe epilepsy, Lennox-Gastaut syndrome, Ras 
mussen’s encephalitis, childhood absence epilepsy, Ramsay 
Hunt syndrome type II, benign epilepsy syndrome, benign 
infantile encephalopathy, benign neonatal convulsions, early 
myoclonic encephalopathy, progressive epilepsy, and infan 
tile epilepsy. 
A patient may suffer from any combination of different 
types of seizures. Partial seizures are the most common type, 
and account for approximately 60% of all seizure types. 
Regardless of the type of epilepsy, seizures signi?cantly limit 
the autonomy of the patient. 
It is believed that the characteristic seizures of epilepsy are 
caused by the disordered, synchronous and rhythmic ?ring of 
brain neurons. The neurons can ?re at up to four times their 
normal rate. As a result, epileptic seizures are an over stimu 
lation of the normal neuronal processes that control brain 
function. 
Anti-epileptic drugs are available for treating epilepsies, 
but these agents have a number of shortcomings. For instance, 
the agents are often poorly soluble in aqueous and biological 
?uids or are extremely hygroscopic. Of even greater impor 
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tance is that patients often become refractory to a drug over 
time. In addition, many anti-epileptic agents cause unWanted 
side effects, neurotoxicities, and drug interactions. Even 
While being treated With one or a combination of the anti 
epileptic drugs currently in clinical use, 30% of epileptic 
patients still experience seizures. As more anti-epileptic 
drugs are developed, the clinician Will have expanded phar 
maceutical options When designing an effective treatment 
protocol for each patient. 
US. Pat. No. 5,677,349 to Gilad et al. discloses methods 
for treating neurotrauma or neurodegenerative disease in a 
human by administering agmatine (4-aminobutylguanidine). 
Neurotrauma and neurodegeneration are terms denoting the 
loss of cells in the brain resulting from an external trauma or 
an external invasive procedure. Examples of neurodegenera 
tion disorders include, for instance, Alzheimer’s disease and 
Parkinson’ s disease, Which result from the decline of neurons 
in the substantia nigra that produce dopamine. The neurode 
generative disorder, amyotrophic lateral sclerosis (ALS), 
results from the degeneration of neurons that control volun 
tary movement. Treatment modalities for epilepsy, hoWever, 
attenuate neuronal activity, i.e., regulate the over stimulation 
of the neuronal processes that control brain function rather 
than treat cell death. Thus, it is believed that Gilad et al. have 
not recognized the use of agmatine in the treatment or pre 
vention of epilepsy, seizure, and other electroconvulsive dis 
orders. 
Accordingly a continuing need exists for pharmaceutical 
compositions that treat or prevent epilepsy and its associated 
symptoms With minimal side-effects. 
SUMMARY OF THE INVENTION 
An advantage and object of the present invention is a phar 
maceutical composition useful for the treatment, prevention 
and/or amelioration of disorders related to and including epi 
lepsy, seizure and other electroconvulsive disorders. 
Additional advantages and features of the invention Will be 
set forth in part in the description Which folloWs and in part 
Will become apparent to those having ordinary skill in the art 
upon examination of the folloWing or may be learned from the 
practice of the invention. The advantages of the invention may 
be realized and obtained as particularly pointed out in the 
appended claims. 
According to the present invention, the foregoing objects 
and advantages are achieved in part by a pharmaceutical 
composition for the treatment or prevention of electroconvul 
sive disorders comprising (i) an effective amount of agma 
tine, an agmatine analog, or a pharmaceutically acceptable 
salt, complex or congener thereof and (ii) a pharmaceutically 
acceptable carrier. Embodiments of the present invention 
include a pharmaceutical composition comprising a dose of 
about 0.1 mg/kg to about 300 mg/kg of agmatine or its phar 
maceutically acceptable salt. 
Another object of the present invention is a method of 
treating, ameliorating, or preventing epilepsy, seizure, or 
electroconvulsive disorders in a subject in need thereof. 
Embodiments of the present invention include administering 
a pharmaceutical composition comprising an effective 
amount of agmatine, an agmatine analog, or a pharmaceuti 
cally acceptable salt thereof in a dose of about 0.1 to about 
500 mg of the active agent per kilogram of a human subject’s 
Weight inde?nitely or until symptoms associated With the 
condition or disorder cease. Additional embodiments of the 
present invention include identifying a human subject in need 
of said treatment, or prevention and preventing, or reducing 
epileptic activity. 
US 7,816,407 B2 
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Additional advantages of the present invention will 
become readily apparent to those skilled in this art from the 
following detailed description, wherein only the preferred 
embodiment of the present invention is shown and described, 
simply by way of illustration of the best mode contemplated 
for carrying out the present invention. As will be realized, the 
invention is capable of other and different embodiments, and 
its several details are capable of modi?cations in various 
obvious respects, all without departing from the present 
invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 graphically illustrates the effective prevention of 
seiZure activity in accordance with an embodiment of the 
present invention. 
DESCRIPTION OF THE INVENTION 
The present invention relates to agmatine (Scheme 1), a 
naturally occurring compound, and to novel congeners, ana 
logs, and derivatives thereof, medicating compositions con 
taining them, and the use thereof, especially in the prevention 
and/ or treatment of all types of seiZures and other electrocon 
vulsive disorders. Agmatine is an amine that is biosyntheti 
cally derived from the decarboxylation of L-arginine by argi 
nine decarboxylase (ADC) (See Scheme 1). 
Scheme 1 
O 
NH Arginine 
Decarboxylase 
HO 1 NH 
NH; NHz co2 
L-Arginine 
NH 
HZN\/\/\ NH 
Agmatine NHZ 
The presence of agmatine in plants, bacteria, and lower life 
forms has been well established. Agmatine and ADC-cata 
lyZed agmatine biosynthesis have also been detected in higher 
organisms, and are present in the brain, liver, kidney, adrenal 
gland, and small intestine of mammals. (Li, G., et al., Agma 
tine: an endogenous clonidine-displacing substance in the 
brain. Science (1994) 263(5149): 966-9; Lortie, M. 1., et al., 
A gmatine, a bioactive metabolite of arginine production, deg 
radation, andfunctional e?‘ects in the kidney ofthe rat, 1. Clin. 
Invest. (1996) 97(2): 413-20; Morrissey, 1., et al., Partial 
cloning and characterization of an arginine decarboxylase in 
the kidney, Kidney Int. (1995) 47(5): 1458-61; Sastre, M., et 
al., Metabolism ofagmatine in macrophages: modulation by 
lipopolysaccharide and inhibitory cytokines, Biochem. 1. 
(1998) 330(Pt 3): 1405-9). Agmatine has been detected in 
several types of human cells, including astrocytes, macroph 
ages, endothelial cells and vascular smooth-muscle cells (Re 
gunathan, S., et al., Imidazoline receptors and agmatine in 
blood vessels: a novel system inhibiting vascular smooth 
muscle proliferation, 1 . Pharmacol. Exp. Ther. (1996) 276(3): 
1272-82; Regunathan, S., et al., Agmatine (decarboxylated 
arginine) is synthesized and stored in astrocytes, Neuroreport 
(1995) 6(14): 1897-900). These results are signi?cant, as they 
indicate that mammalian agmatine is endogenously derived, 
and not of dietary or bacterial origin. 
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Although the physiological roles of agmatine are still 
under investigation, it is evident that agmatine exerts a wide 
range of biological activities, including those which may 
affect the function of the central nervous system (CNS). At 
least three possible physiological roles of agmatine have been 
identi?ed. Agmatine may play a role in cell signaling, since it 
interacts with (x2-adrenergic, imidaZoline and N-methyl-D 
aspartate (NMDA) receptors. (Li, G., et al., Agmatine: an 
endogenous clonidine-displacing substance in the brain, Sci 
ence (1994) 263(5149):966-9; Anis, N., et al., Structure-ac 
tivity relationships ofphilanthotoxin analogs andpolyamines 
on N-methyl-D-aspartate and nicotinic acetylcholine recep 
tors, 1. Pharmacol. Exp. Ther. (1990) 254(3):764-73). Con 
sequently, it has been hypothesiZed that agmatine may be a 
CNS neurotransmitter or neuromodulator in neurons 
involved in behavioral and visceral control. (Reis, D. 1. and S. 
Regunathan, A gmati ne: a novel neurotransmitter? Adv. Phar 
macol. (1998) 42:645-9; Reis, D. 1. and S. Regunathan, 
Agmatine: an endogenous ligand at imidazoline receptors 
may be a novel neurotransmitter in brain. 1. Auton. Nerv. 
Syst. (1998) 72(2-3):80-5). 
Another physiological role of agmatine is that of regulating 
polyamine synthesis. By inducing the synthesis of antiZyme, 
agmatine inhibits the enZyme ornithine decarboxylase, the 
rate-limiting enZyme in polyamine biosynthesis. (Satriano, 
1., et al., Agmatine suppresses proliferation by frameshift 
induction ofantizyme and attenuation ofcellularpolyamine 
levels, 1. Biol. Chem. (1998) 273(25):15313-6). Polyamines 
exert a wide range of activities in numerous organ systems, 
including the central nervous system. Polyamines regulate 
cell proliferation, modulate postsynaptic receptors (such as 
NMDA, nicotinic, and benZodiaZepine receptors), and have 
antiplatelet, anti-in?ammatory, and anticoagulant activity. In 
addition, agmatine is a competitive inhibitor of nitric oxide 
synthase isoenZymes. (Galea, E., et al., Inhibition ofmamma 
lian nitric oxide synthases by agmatine, an endogenous 
polyamine formed by decarboxylation of arginine, Biochem. 
1. (1996) 316(Pt 1):247-9). The cell signaling and ncuro 
modulatory properties of nitric oxide have been extensively 
reviewed. (Kerwin, 1. E, et al., Nitric oxide: a new paradigm 
for second messengers, 1. Med. Chem. (1995) 38(22):4343 
62; MacMicking, 1., et al., Nitric oxide and macrophage 
function, Ann. Rev. Immunol. (1997) 15:323-50; Stuehr, D. 
1., Structure-function aspects in the nitric oxide synthases, 
Ann. Rev. Pharmacol. Toxicol. (1997) 37:339-59). 
After experimentation and investigation, it was discovered 
that administration of exogenous agmatine to rats resulted in 
profound and reproducible anticonvulsant or antiepileptic 
activity in animal models of seiZure disorders. It was further 
discovered that, despite the integral role that agmatine 
appears to play in the function of the central nervous system 
and other organ systems, no toxic effects were observed in 
any of the animal studies as a result of the systemic adminis 
tration of agmatine. 
These discoveries contributed to the present invention 
where it is contemplated that a human subject suffering from 
or susceptible to epilepsy, seiZure and other electroconvulsive 
disorders can be treated by administering a pharmaceutical 
composition including an effective amount of agmatine, an 
agmatine analog, or a pharmaceutically acceptable salt 
thereof to treat, reduce, or prevent the disorder in the subject. 
In one aspect of the present invention, a human subject is 
identi?ed as having or being susceptible to the disorder prior 
to the administration of the active agent. 
The diagnosis of a human subject that is susceptible or in 
need of such treatment is well known in the medical arts and 
includes, for example, genetic analysis, electrophysiological 
US 7,816,407 B2 
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analysis, genealogy, etc. The diagnosis can include obtaining 
and analyzing a potential human subject’s electroencephalo 
gram (EEG), as is knoWn in the art, to determine the suscep 
tibility of seizure or the actual occurrence of a seizure. The 
diagnosis can also include observing the characteristic mani 
festations, symptoms, or features associated With the various 
forms of epileptic seizures. The observation can be made by 
the subject himself or herself, a medical practitioner or any 
other observer capable of making such observations and 
determinations. Illustrative characteristic features of various 
epileptic seizures are presented in Table 1 below. 
TABLE 1 
SEIZURE 
TYPE FEATURES 
Simple Diverse manifestations determined by the region of cortex 
partial activated by seizure (e. g., if motor cortex representing left 
thumb, clonic jerking of left thumb results; if 
somatosensory cortex representing left thumb, paresthesias 
of left thumb results), lasting approximating 20 to 60 
seconds. A key feature is preservation of consciousness. 
Complex Impaired consciousness lasting about 30 seconds to about 
partial one to about tWo minutes, often associated With purposeless 
movements such as lip smacking or hand wringing. 
Partial With Simple or complex partial seizure evolves into a tonic 
secondarily clonic seizure With loss of consciousness and sustained 
generalized contractions (tonic) of muscles throughout the body 
tonic-clonic followed by periods of muscle contraction alternating With 
seizure periods of relaxation (clonic), typically lasting about 1 to 2 
minutes. 
Absence Abrupt onset of impaired consciousness associated With 
seizure starting and cessation of ongoing activities typically lasting 
less than 30 seconds. 
Myoclonic A brief (perhaps a second), shock-like contraction of 
seizure muscles Which may be restricted to part of one extremity or 
may be generalized. 
As described above for partial With secondarily generalized 
tonic-clonic seizures except that it is not preceded by a 
partial seizure. 
Tonic-clonic 
seizure 
In practicing the present invention, agmatine, an agmatine 
analog, or a pharrnaceutically acceptable salt, complex or 
cogener thereof is formulated into a pharmaceutical prepara 
tion comprising the active agent and a pharrnaceutically 
acceptable carrier. It has been discovered that the inventive 
compositions are useful in the prevention, palliation and/or 
treatment of seizures, conduction disturbances, and electro 
convulsive disorders of all types, and their manifestations 
irrespective of the origin of the aliment in a subject in need 
thereof including humans and other mammals. It is contem 
plated that the inventive compositions can be employed for 
preventing and/or treating other conduction disturbances of 
the CNS, and the emotional, cognitive, and motor symptoms 
resulting therefrom. 
In an embodiment of the present invention, the inventive 
compositions are administered to a subject, eg a human 
subject, in need thereof to prevent or treat disturbances of the 
CNS, such as seizure and electroconvulsive disorders, of 
either or both an acute or chronic nature, of unknoWn origin or 
secondary to conditions such as, but not limited to: surgery, 
irradiation or other manipulation of the brain and/or CNS; 
alcohol, benzodiazepine, barbiturate or other drug or chemi 
cal WithdraWal; exposure to epileptogenic drugs and/or 
chemicals; acute or chronic injury or trauma; stroke or cere 
brovascular accident; fever; meningitis or other CNS in?am 
mation or infection; or electroconvulsive therapy. 
In practicing the present invention, agmatine, an agmatine 
analog, or a pharamceutically acceptable salt thereof is for 
mulated into a pharmaceutical composition. In an embodi 
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ment of the present invention, agmatine and agmatine analogs 
are provided by Formula I beloW: 
Formula I 
NR3 
R IRZN 
Wherein n is 0 to about 10; R1, R2, R3, R4, and R5, are each 
independently, or any combination thereof: hydrogen, 
hydroxy, substituted or unsubstituted C HO alkyl, substituted 
or unsubstituted C3_8 cycloalkyl, substituted or unsubstituted 
arylalkyl (comprising Ari(CH2)m; WhereAr is aromatic and 
m is 0 to about 10) substituted or unsubstituted C MO alkoxyl, 
substituted or unsubstituted C 1_ 1 O acyl, halogeno, amido, phe 
nyl, thio, amino, or nitro including racemic, diastereomeric, 
and all enantiomeric forms. In a preferred embodiment, R1 
and R2 represent Rli(CH2)niR2 Where n is 3-8 and R3 and 
R5 represent R3i(CH2)niR5 Where n is 3-8. X andY are 
each independently: O, NH, CH2, CF2, Se, C:O, C:N, 
C:S, or S; or XiY together is HC:CH, CEC, N:N, 
N:CH, CH:N, or a saturated or unsaturated ring including 
all geometric and stereoisomers thereof. 
In an embodiment of the present invention, XiY is a 
saturated ring including, but not limited to: cyclobutane, 
cyclopentane, cyclohexane, cycloheptane, cyclooctane, azet 
ine, piperdine, pyrazolidine, imidazoline, piperazine, pipra 
zine, hexa-hydropyrimidine, thietane, thiophane, 1,3-dithi 
olane, 1,2-dithiolane, thiane, 1,2-dithiane, 1,3-dithane, 1,4 
dithiane, tetrahydrofuran, tetrahydropyran, 1,4-dioxane, 1,3 
dioxane and 1,4-oxathinin, oxetane, morpholine, 
imidazoline, oxazoline, and thiazolidine, including all pos 
sible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric and enantiomeric forms thereof. 
In an embodiment of the present invention, XiY is an 
unsaturated hydrocarbon ring including, but not limited to 
benzene, cyclopentene, cyclohexene, cycloheptene, 
cyclooctene, cyclopentadiene, including all possible substi 
tution patterns, geometric and stereoisomers, racemic, dias 
tereomeric, and enantiomeric forms thereof. 
In an embodiment of the present invention, XiY is an 
unsaturated nitrogen heterocycle, including but not limited 
to, pyrrole, pyrrolidine, pyrazole, imidazole, 1,2,3-triazole, 
1,2,4-triazole, pyridine, pyridazine, pyrimidine, pyrazine, tri 
azine, indole, indazole, pteridine, quinoline, quinazoline, 
benzodiazepine, acridine, benzimidazole, purine, iso 
quinazoline, and isoquinoline, including all possible substi 
tution patterns, geometric and stereoisomers, racemic, dias 
tereomeric and enantiomeric forms thereof. 
In an embodiment of the present invention, XiY is an 
unsaturated oxygen heterocycle, including but not limited to 
furan, 2,5-dihydrofuran, or pyran including all possible sub 
stitution patterns, geometric and stereoisomers, racemic, 
diastereomeric, and enantiomeric forms thereof. 
In an embodiment of the present invention, XiY is an 
unsaturated sulfur containing heterocycle, including but not 
limited to, thiophene, 2,5-dihydrothiophene, 1,2-dithioly 
lium, 1,3-dithiolylium, thiopyranylium, including all pos 
sible substitution patterns, geometric and stereoisomers, 
racemic, diastereomeric, and enantiomeric forms thereof. 
In an embodiment of the present invention, XiY is an 
unsaturated selenium containing heterocycle, including but 
not limited to selenophene including all possible substitution 
patterns, geometric and stereoisomers, racemic, diastereo 
meric, and enantiomeric forms thereof. 
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In an embodiment of the present invention, XiY is an 
unsaturated mixed heterocycle, including but not limited to 
thiaZole, benZothiaZole, benZoxaZole, thiadiaZole, phenothi 
aZine, isoxaZole, 2-oxaZoline, oxaZole and oxaZin including 
all possible substitution patterns, geometrical, and stereoiso 
mers, racemic, diastereomeric and enantiomeric forms 
thereof. 
Agmatine can be isolated from naturally occurring sources 
or synthetically prepared by conventional techniques. Agma 
tine analogs can be synthetically prepared by conventional 
synthesis as disclosed by US. Pat. No. 5,677,349 the entire 
disclose of Which is hereby incorporated by reference. 
Salt forms of agmatine and its analogs include, but are not 
limited to, the following: inorganic acid addition salts such as 
hydrochloride, hydrobromide, sulfate, phosphate, and nitrate; 
organic acid addition salts such as acetate, galactarate, pro 
pionate, succinate, lactate, glycolate, malate, tartrate, citrate, 
maleate, fumarate, methanesulfonate, salicylate, p-toluene 
sulfonate, benZenesulfonate, and ascorbate; salts With acidic 
amino acids such as aspartate and glutamate; the salts may be 
in some cases hydrates or solvates With alcohols and other 
solvents. Salt forms of agmatine for an agmatine analog can 
be prepared by admixing the acid With agmatine for its analog 
in a conventional solvent or equivalent thereof, With or With 
out alcohols or Water. 
The compounds of the present invention are useful in phar 
maceutical compositions for systemic administration to 
mammals including humans as a single agent, or as a primary 
or adjunct agent With any other medication, chemical, drug or 
non-drug therapy, or combination thereof. 
The aforementioned administration of agmatine, agmatine 
analogs or pharmaceutically acceptable salt thereof is to be 
employed acutely, or as a single dose, or administered inter 
mittently, or on a regular schedule of unspeci?ed duration, or 
by continuous infusion of unspeci?ed duration, by any 
acceptable route of administration including, but not limited 
to, parenteral, oral, buccal, intranasal, pulmonary, transder 
mal, rectal, vaginal, intradermal, intrathecal, intravenous, 
intramuscular and/ or subcutaneous routes. 
The pharmaceutical preparations can be employed in unit 
dosage forms, such as tablets, capsules, pills, poWders, gran 
ules, suppositories, sterile parenteral solutions or suspen 
sions, sterile non-parenteral solutions or suspensions oral 
solutions or suspensions, oil in Water or Water in oil emulsions 
and the like, containing suitable quantities of an active ingre 
dient. Topical application can be in the form of ointments, 
creams, lotions, jellies, sprays, douches, and the like. For oral 
administration either solid or ?uid unit dosage forms can be 
prepared With the compounds of Formula 1. 
Either ?uid or solid unit dosage forms can be readily pre 
pared for oral administration. For example, the compounds 
can be mixed With conventional ingredients such as dicalci 
umphosphate, magnesium aluminum silicate, magnesium 
stearate, calcium sulfate, starch, talc, lactose, acacia, methyl 
cellulose and functionally similar materials as pharmaceuti 
cal excipients or carriers. A sustained release formulation 
may optionally be used. Capsules may be formulated by 
mixing the compound With a pharmaceutical diluent, Which is 
inert and inserting this mixture into a hard gelatin capsule 
having the appropriate siZe. If soft capsules are desired, a 
slurry or other dispersion of the compound With an acceptable 
vegetable, light petroleum, or other inert oil can be encapsu 
lated by machine into a gelatin capsule. 
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Suspensions, syrups, and elixirs may be used for oral 
administration of ?uid unit dosage forms. A ?uid preparation 
including oil may be used for oil soluble forms. A vegetable 
oil such as corn oil, peanut oil, or saf?oWer oil, for example, 
together With ?avoring agents, sWeeteners and any preserva 
tives produces an acceptable ?uid preparation. A surfactant 
may be added to Water to form a syrup for ?uid unit dosages. 
Hydro-alcoholic pharmaceutical preparations may be used 
having an acceptable sWeetener such as sugar, saccharine, or 
a biological sWeetener and a ?avoring agent in the form of an 
elixir. 
Pharmaceutical compositions for parenteral and supposi 
tory administration can also be obtained using techniques 
standard in the art. Another preferred use of the compounds is 
in a transdermal parenteral pharmaceutical preparation in a 
mammal such as a human. 
The above and other drugs can be present in the reservoir 
alone or in combination form With pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of this 
invention are the art knoWn carriers that do not adversely 
affect the drug, the host, or the material comprising the drug 
delivery device. Suitable pharmaceutical carriers include 
sterile Water; saline, dextrose; dextrose in Water or saline; 
condensation products of castor oil and ethylene oxide com 
bining about 30 to about 35 moles of ethylene oxide per mole 
of castor oil; liquid acid; loWer alkanols; oils such as corn oil; 
peanut oil, sesame oil and the like, With emulsi?ers such as 
mono- or di-glyceride of a fatty acid, or a phosphatide, e.g., 
lecithin, and the like; glycols; polyalkylene glycols; aqueous 
media in the presence of a suspending agent, for example, 
sodium carboxymethylcellulose; sodium alginate; poly(vi 
nylpyrolidone); and the like, alone, or With suitable dispens 
ing agents such as lecithin; polyoxyethylene stearate; and the 
like. The carrier may also contain adjuvants such as preserv 
ing stabiliZing, Wetting, emulsifying agents and the like 
together With the penetration enhancer of this invention. 
By “effective amount , therapeutic amount” or “effective 
dose” is meant that amount su?icient to elicit the desired 
pharmacological or therapeutic effects, thus resulting in 
effective prevention or treatment of the condition or disorder. 
Thus, When treating a CNS disorder, an effective amount of a 
compound is that amount suf?cient to pass across the blood 
brain barrier of the subject to bind to relevant receptor sites in 
the brain of the subject or otherWise affect the brain. Preven 
tion of the condition or disorder is manifested by delaying the 
onset of the symptoms of the conditions or disorder. Treat 
ment of the condition or disorder is manifested by a decrease 
in the symptoms associated With the condition or disorder, or 
an amelioration of the recurrence of the symptoms of the 
condition or disorder. 
The effective dose can vary, depending upon factors such 
as the condition of the patient, the severity of the symptoms of 
the disorder, age, Weight, and the manner in Which the phar 
maceutical composition is administered. Typically, the effec 
tive dose of compounds generally requires administering the 
compound in an amount of about 0.1 to about 500 mg per 
kilogram of the subject’s Weight. In an embodiment of the 
present invention, the a dose of about 0.1 to about 300 mg/kg 
is administered per day inde?nitely or until symptoms asso 
ciate With the condition or disorder cease. Preferably about 
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1.0 to about 50 mg per kilogram body Weight is administered 
per day. The required dose is less When administered 
parenterally. 
EXAMPLES 
Example 1 
The Maximal Electroshock Seizure (MES) or 
Maximal Seizure Pattern Test 
The MES is an experimental model for generalized tonic 
clonic seizures that identi?es compounds Which prevent sei 
zure spread. The MES model is highly reproducible and has a 
consistent endpoint. An advantage of this model is that the 
behavioral and electrographic seizures are consistent With 
those observed in humans (Levy, R. H., Antiepileptic drugs. 
3rd Ed. 1989, NeW York: Raven Press. xxvii, 1025. p. 
85 -102). 
In the MES test, the animal receives an electrical stimulus, 
0.2 seconds in duration, via corneal electrodes primed With an 
electrolyte solution containing an anesthetic agent. The 0.2 
second stimulation is generated With 150 mA in rats at 60 Hz. 
TWenty rats, Weighing betWeen 105 g and 130 g receive an 
electrical stimulus 15 minutes, 30 minutes, 1 hour, 2 hours, 4 
hours, 8 hours and 12 hours after oral administration of a dose 
of about 30 mg/kg of agmatine in phosphate buffered in saline 
per kg of the animal. The test endpoint, electrogenic seizure, 
is manifested as hindlimb tonic extension. Inhibition of hind 
limb tonic extension indicates that the test compound is able 
to inhibit MES-induced seizure spread Which in turn is 
indicative of antiseizure activity (Levy, R. H., Antiepileptic 
drugs. 3rd Ed. 1989, NeW York: Raven Press. xxvii, 1025. p. 
85-102; Levy, R. H., et al., Antiepileptic drugs. 4th Ed. 1995, 
NeWYork: Raven Press. xxv, 1120. p. 99-1 10; White, H. S., et 
al., The early identification ofanticonvulsant activity: role of 
the maximal electroshock and subcutaneous pentylenetetra 
zol seizure models. Ital. J. Neurol. Sci. (1995) 16(1-2):73-7). 
The results of the MES test demonstrate that agmatine is 
effective in preventing seizure spread in the rat. As shoWn in 
FIG. 1, an oral agmatine dose of 30 mg/kg prevented seizure 
spread in 37.5% of the rats Which received a shock 0.25 hours 
after agmatine administration. At 0.5 hours after agmatine 
administration, 12.5% of the rats Were protected, While at 1 
hour after oral agmatine administration, none of the rats Were 
protected from seizure spread after receiving the electrical 
stimulus. Notably, at 2, 4, and 6 hours after agmatine admin 
istration, protection from MES-induced seizure spread Was 
again observed as 12.5%, 75% and 25%, respectively, of the 
animals in each group. These data indicate that the oral 
administration of agmatine (30 mg/kg) may have both acute 
(0-1 hours) and delayed (2-6 hours) inhibitory effects on 
MES-induced seizure spread. Additionally, the administra 
tion of intraperitoneal agmatine 4 hours before receiving an 
electrical shock prevented seizure spread in 50% of rats so 
treated, indicating that the protection from MES-induced sei 
zures by agmatine can be observed When the compound is 
give via a route other than the oral route. 
Example 2 
Minimal Neurotoxicity 
Toxicity in mice and rats is assessed using three screens: 
the rotorod in mice, positional sense, and gait in rats. In mice, 
the test compound is administered at doses of 30, 100, and 
300 mg/kg prior to evaluation in the toxicity screens. The 
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mice are tested 0.5 hours and 4 hours after administration of 
the test compound. In rats, the test compound is administered 
at 30 mg/kg prior to the toxicity assessment. The rats are 
tested at 0.25, 0.5, 1, 2, and 4 hours after administration of the 
test compound. 
Rotorod Test 
Toxicity in mice Weighing betWeen 20.5 and 25.5 g is 
assessed using the standardized rotorod test (Dunham, M. S. 
and T. A. Miya, A note on a simple apparatusfor detecting 
neurological de?cit in rats and mice, J. Am. Pharm. Assoc. 
Sci. Edit (1957) 46:208-209). Control mice can maintain their 
equilibrium for an extended period of time When they are 
placed on a 6 rpm rotation rod. Neurologically impaired 
animals cannot maintain equilibrium for one minute in each 
of three successive trials. 
Positional Sense Test 
Behavioral toxicity in rats Weighing betWeen 105 and 130 
g is assessed by the positional sense test. In this test, one hind 
leg is gently loWered over the edge of a table. If the rat 
experiences neurological toxicity, it Will not be able to 
quickly lift its leg back to a normal position. 
Gait and Stance Test 
In the gait and stance test, neurotoxicity is indicated by a 
circular or zigzag gait after administration of the test com 
pound. In addition, ataxia, abnormal spread of the legs, abnor 
mal posture, tremor hyperactivity, lack of exploratory behav 
ior, somnolence, stupor, or catalepsy can indicate 
neurotoxicity. This toxicity test Was conducted on 20 rats, 
Weighing betWeen 105 and 130 g. 
In rats and mice, agmatine Was demonstrated to be devoid 
of any neurological toxicity related to the assays described 
above. Twenty-four mice, received agmatine doses as high as 
300 mg/kg. As quanti?ed by the rotorod neurotoxicity test, 
none of these animals shoWed any evidence of behavioral or 
neurotoxicity. Similarly, agmatine shoWed no neurotoxicity 
in rats. Forty rats received either oral or intraperitoneal agma 
tine at a dose of 30 mg/kg. As assessed by the positional sense 
and the gait and stance tests, these data suggest that agmatine 
is not neurotoxic. 
While the present invention has been described in connec 
tion With What is presently considered to be the most practical 
and preferred embodiments, it is to be understood that the 
invention is not limited to the disclosed embodiments and 
examples. It should be apparent to those of skill in the art that 
various modi?cations and variations may be made to the 
composition and method of the present invention Without 
departing from the spirit or scope of the invention. All rel 
evant portions of patents and publications cited herein are 
incorporated by reference in their entireties. 
What is claimed is: 
1. A method of treating, ameliorating, or preventing sei 
zures associated With epilepsy in a subject in need thereof, the 
method comprising: 
administering a pharmaceutical composition comprising 
about 0.1 to about 500 mg of agmatine or an agmatine 
analog, or a pharmaceutically acceptable salt thereof per 
kilogram of the subject’s Weight to treat, reduce, or 
prevent seizures associated With epilepsy in the subject, 
Wherein the agmatine analog has the folloWing formula 
US 7,816,407 B2 
11 
wherein n is 0 to about 10; 
R1, R2, R3, R4, and R5, are each independently, or any 
combination thereof: hydrogen, hydroxy, substituted or 
unsubstituted Cl_1O alkyl, substituted or unsubstituted 
C3_8 cycloalkyl, substituted or unsubstituted arylalkyl 
(comprising Ari(CH2)m; WhereAr is aromatic and m is 
0 to about 10) substituted or unsubstituted C 1_ 1O alkoxyl, 
substituted or unsubstituted C MO acyl, halogeno, 
amido, phenyl, thio, or amino; and 
X andY are each independently: O, NH, CH2, CF2, Se, 
C:O, C:N, or C:S, or XiY together is HC:CH, 
CEC, N:N, N:CH, CH:N, or a saturated or unsat 
urated ring. 
2. A method according to claim 1, Wherein the pharmaceu 
tical composition comprises agmatine or its pharmaceutically 
acceptable salt and a pharmaceutically acceptable carrier. 
3. A method according to claim 2, Wherein the composition 
is administered in a dose of about 0.1 to about 50 mg/kg per 
day inde?nitely or until seiZures associated With the epilepsy. 
4. A method according to claim 1, comprising preventing 
or reducing seiZure activity. 
5. A method of treating or preventing seiZures associated 
With epilepsy in a human comprising: 
identifying a human subject in need of said treatment or 
prevention; and 
administering about 0.1 to about 500 mg of agmatine or an 
agmatine analog, or a pharmaceutically acceptable salt 
thereof per kilogram of the subject’s Weight to the 
human subject, Wherein the agmatine analog has the 
folloWing formula 
NR3 
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Wherein n is 0 to about 10; 
R1, R2, R3, R4, and R5, are each independently, or any 
combination thereof: hydrogen, hydroxy, substituted or 
unsubstituted Cl_1O alkyl, substituted or unsubstituted 
C3_8 cycloalkyl, substituted or unsubstituted arylalkyl 
(comprising Ari(CH2)m; WhereAr is aromatic and m is 
0 to about 10) substituted or unsubstituted C 1_ 1O alkoxyl, 
substituted or unsubstituted C MO acyl, halogeno, 
amido, phenyl, thio, or amino; and 
X and Y are each independently: O, NH, CH2, CF2, Se, 
C:O, C:N, or C:S, or XiY together is HC:CH, 
CEC, N:N, N:CH, CH:N, or a saturated or unsat 
urated ring. 
6. A method according to claim 5, comprising identifying a 
human subject in need of said treatment by analyZing an 
electroencephalogram taken of the human subject. 
7. A method according to claim 5, comprising identifying a 
human subject in need of said treatment by observing the 
occurrence of a seiZure in said subject. 
8. A method according to claim 5, comprising administer 
ing the effective amount of agmatine, an agmatine analog or 
a pharmaceutically acceptable salt thereof to the human sub 
ject inde?nitely or until the seiZures associated With epilepsy 
cease. 
9. A method according to claim 5, comprising preventing 
or reducing seiZures associated With epileptic activity. 
10. A method according to claim 5, comprising adminis 
tering the effective amount of agmatine, an agmatine analog 
or a pharmaceutically acceptable salt thereof as a pharmaceu 
tical composition. 
11. A method according to claim 5, comprising adminis 
tering the effective amount of agmatine, an agmatine analog 
or a pharmaceutically acceptable salt thereof parenterally. 
12. A method according to claim 5, comprising adminis 
tering the effective amount of agmatine, an agmatine analog 
or a pharmaceutically acceptable salt thereof orally. 
* * * * * 
